{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-010358","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.423284+00:00","generated_at":"2026-05-24T00:54:30.146689+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eton out-licenses international rights to Increlex to Esteve for €4M upfront","bullets":["Esteve pays €4M upfront; license runs up to ten years with option to buy international rights for up to €6M.","Eton supplies Increlex at a fixed transfer price; no change to expected $80M annual revenue run rate exiting 2025.","Deal lets Eton focus on three rare-disease product launches planned in the U.S. for 2025.","Eton eliminates need for significant ex-U.S. commercialization infrastructure investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-010358","json":"https://secwatch.observer/filing/0001437749-25-010358.json","markdown":"https://secwatch.observer/filing/0001437749-25-010358.md","text":"https://secwatch.observer/filing/0001437749-25-010358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/0001437749-25-010358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/eton20250321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:54:30.146689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}